pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·1d ago·1 min read
save

Merck acquires Silence Therapeutics for $1.3B; Hansoh Pharma signs $15B deal with Roche

Oct 19, 2026·read at raps ↗DealNeutral

German Merck announced the acquisition of Silence Therapeutics in a transaction valued at $1.3 billion.

In China, Hansoh Pharma disclosed a partnership with Roche that involves a $15 billion drug deal.

Both announcements were highlighted in a regulatory news briefing.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “Recon: German Merck acquires Silence Therapeutics for $1.3B; China's Hansoh Pharma strikes $15B drug deal with Roche”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ROCHE2Silence Therapeutics plc2

related stories

  • 15h agoDisc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweepBioSpace
  • 15h agoDisc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweepBioSpace
  • May 18FDA approves AstraZeneca’s new kind of hypertension drugBioPharma Dive
  • May 15Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workersBioPharma Dive
  • May 14BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at VenclextaEndpoints